Johnson & Johnson (JNJ) Position Raised by Edgewood Management LLC

Edgewood Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 0.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,401 shares of the company’s stock after buying an additional 43 shares during the period. Edgewood Management LLC’s holdings in Johnson & Johnson were worth $4,079,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Stokes & Hubbell Capital Management LLC boosted its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Stokes & Hubbell Capital Management LLC now owns 89,666 shares of the company’s stock valued at $10,592,000 after buying an additional 269 shares during the last quarter. Oliver Luxxe Assets LLC boosted its stake in shares of Johnson & Johnson by 3.6% in the third quarter. Oliver Luxxe Assets LLC now owns 14,651 shares of the company’s stock valued at $1,731,000 after buying an additional 512 shares during the last quarter. Pure Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 16.1% in the third quarter. Pure Financial Advisors Inc. now owns 3,399 shares of the company’s stock valued at $401,000 after buying an additional 472 shares during the last quarter. Bremer Trust National Association boosted its stake in shares of Johnson & Johnson by 1.9% in the third quarter. Bremer Trust National Association now owns 22,727 shares of the company’s stock valued at $2,685,000 after buying an additional 432 shares during the last quarter. Finally, Independence Advisors LLC boosted its stake in shares of Johnson & Johnson by 52.5% in the third quarter. Independence Advisors LLC now owns 6,244 shares of the company’s stock valued at $738,000 after buying an additional 2,150 shares during the last quarter. Institutional investors own 65.30% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.02% during midday trading on Friday, hitting $121.89. 4,372,497 shares of the stock were exchanged. The firm’s 50 day moving average is $125.22 and its 200-day moving average is $118.10. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $129.00. The stock has a market capitalization of $330.73 billion, a price-to-earnings ratio of 20.55 and a beta of 0.74. Johnson & Johnson also was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 3,039 put options on the stock. This represents an increase of approximately 415% compared to the average volume of 590 put options.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.06. The firm had revenue of $17.77 billion for the quarter, compared to analysts’ expectations of $18.02 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 earnings per share. On average, analysts predict that Johnson & Johnson will post $7.04 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/04/21/edgewood-management-llc-boosts-stake-in-johnson-johnson-jnj-updated-updated.html.

Several brokerages have commented on JNJ. Jefferies Group LLC reiterated a “hold” rating and set a $132.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Saturday, March 11th. Barclays PLC reissued an “equal weight” rating and issued a $130.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a report on Monday. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $119.73 price target for the company. in a report on Tuesday, March 7th. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Wednesday. Finally, Royal Bank of Canada reissued a “buy” rating and issued a $133.00 price target on shares of Johnson & Johnson in a report on Friday, January 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $125.53.

In other news, VP Paulus Stoffels sold 22,000 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the sale, the vice president now owns 127,650 shares in the company, valued at $14,972,068.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

5 Day Chart for NYSE:JNJ

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit